Moleculin Biotech to effect 1-for-20 reverse stock split effective October 20, 2026
Moleculin Biotech's 1-for-20 reverse stock split takes effect at 12:01 a.m. Eastern Time on October 20, 2026, and the stock will keep the MBRX ticker under a new CUSIP. Shares outstanding will fall from approximately 20.91 million to approximately 1.05 million, and proportional adjustments will apply to outstanding options, RSUs, warrants and the equity plan reserve, while authorized shares stay at 500 million.
Key points
- Effective 12:01 a.m. ET on October 20, 2026; trading on The Nasdaq Capital Market under MBRX with new CUSIP 60855D507
- Shares outstanding reduced from approximately 20.91 million to approximately 1.05 million; authorized shares remain at 500 million
- Stockholders approved a split ratio range of 1-for-2 to 1-for-20 at the annual meeting completed October 9, 2026; the board selected 1-for-20
- Fractional shares will be paid in cash based on the average closing price over the five trading days before the split
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 20, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.